Eisai expands R&D in Belgium with office in Brussels
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 16 Sep, 2013
Singapore: Eisai EMEA (Europe, Middle East, Africa, Russia and Oceania), the R&D division of the Japan-based company...Read more
Genzyme's Cerdelga capsules approved in Japan
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 01 Apr, 2015
Genzyme, a Sanofi company, announced that the Ministry of Health, Labour and Welfare (MHLW) has granted marketing approv...Read more
GE to open technology and training centre in Turkey
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 17 Nov, 2014
Singapore: GE Healthcare Life Sciences plans to open a technology and training laboratory in Turkey by mid-2015 targetti...Read more
Takeda terminates prostrate cancer drug trial
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 24 Jun, 2014
Singapore: Takeda Pharmaceutical has terminated the development program for orteronel (TAK-700) for prostate cancer foll...Read more
Panacea JV to yield generics revenue of $25 bn
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 12 Sep, 2012
New Delhi: Panacea Biotec entered into a strategic alliance for R&D and commercialization of drug delivery-based, ge...Read more
Fosun Pharma listed in CCTV Financial 50 Index Sample Stock
Drug Discovery | Company results | By BioSpectrum Bureau | 10 Comment | 14 Aug, 2013
Singapore: Shanghai Fosun Pharmaceutical has been listed in CCTV Financial 50 Index Sample Stock, an index created by Sh...Read more
Military univ, Shanghai Pharma form alliance
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 01 Aug, 2013
Singapore: Shanghai Pharmaceuticals has entered into a strategic framework cooperation agreement with Secondary Military...Read more
Singapore, Korea scientists find clue to tumour suppression mechanism
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 12 Nov, 2013
Singapore: RUNX3, a gene that is intensively studied for its function as a tumour suppressor, is likely to be a key and ...Read more
Ranbaxy redesigns strategy to meet regulations
Drug Discovery | Analysis | By BioSpectrum Bureau | 3 Comment | 12 Jun, 2012
The year 2011 was a year of capturing potential markets and achieving new milestones. Ranbaxy Laboratories became the fi...Read more
Patrys gets nod to continue myeloma trial
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 24 Apr, 2013
Singapore: Patrys received approval to progress its phase I/IIa PAT-SM6 multiple myeloma trial based on safety data from...Read more
TB Alliance starts clinical trial of drug resistant TB
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 14 May, 2015
Singapore: TB Alliance has started a clinical trial of a new regimen to treat extensively drug-resistant tuberculosis (X...Read more
Ignyta acquires Teva's upcoming oncology program at $41.6 mn
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 24 Apr, 2016
Singapore: US based oncology biotechnology company, Ignyta, has acquired four targeted oncology development programs fro...Read more
US firm files antibody patent in Japan, Korea
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 27 Aug, 2013
Singapore: MMRGlobal received confirmation of the filings of a divisional application for its antibody technology in Jap...Read more
Sphaera Pharma, DDRC, Wellcome Trust collaborate to foster TB research
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 10 Aug, 2015
Singapore: In a bid to further foster new drug research for drug resistant tuberculosis (TB), Wellcome Trust has collabo...Read more
J&J to open innovation centers in US, UK and China
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 19 Sep, 2012
Singapore: Johnson & Johnson plans to establish four regional innovation centers in major life sciences communities ...Read more
Amgen progresses on Ph II study of migraine drug
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 18 May, 2015
Singapore: Amgen has received positive results from its global Phase 2 clinical trial of AMG 334, a fully human monoclon...Read more
OccuRx kick starts with $5.21 mn investment
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 18 May, 2015
Singapore: OccuRx, an Australian biopharmaceutical company developing a new class of drugs to prevent health burden due ...Read more
Nektar's therapy helps the body kill its own cancer
Drug Discovery | News | By BioSpectrum Bureau | 0 Comment | 09 Apr, 2013
Singapore: US-based Nektar Therapeutics has revealed positive preclinical data for NKTR-214, a novel cancer immunotherap...Read more